Abstract: Objective Despite accumulating evidence on a role of immune cells and their associated chemicals in mechanisms of pain, few studies have addressed the potential role of chemokines in the descending facilitation of persistent pain. The present study was undertaken to test the hypothesis that the chemokine (C-C motif) ligand 2 (CCL2) (commonly known as monocyte chemoattractant protein-1) signaling in the rostral ventromedial medulla (RVM), a pivotal structure in brainstem pain modulatory circuitry, is involved in descending pain facilitation in rats. Methods An L5 spinal nerve ligation (SNL) was produced in rats under pentobarbital anesthesia. Western blot and immunohistochemistry were used to detect the expression levels of CCL2 and CCL2 receptor (CCR2), and examine their distributions compared with the neuronal marker NeuN as well as glial markers glial fibrillary acidic protein (GFAP, astroglial) and CD11b (microglial), respectively. Results SNL induced an increase in CCL2 expression in the RVM, and this returned to the control level at 4 weeks after injury. The induced CCL2 colocalized with NeuN, but not with GFAP and CD11b. CCR2 was also upregulated by SNL in the RVM, and this increase lasted for at least 4 weeks. CCR2 was colocalized with CD11b but not GFAP.
aged into large dense-core vesicles in dorsal root ganglion neurons [16] , suggesting that it can be released in a manner similar to a neurotransmitter. In fact, there is an increased synaptic release of CCL2 from capsaicin-sensitive primary afferent fibers in spinal dorsal horn slices in sciatic nerve-injured rats [17] . Interestingly, expression of CCL2 in neurons is inducible [14, 18, 19] and activation of CCL2 receptor chemokine (C-C motif) receptor 2 (CCR2, CD192) on microglia contributes to neuropathic pain [20, 21] . CCL2 is also induced in spinal astrocytes by spinal contusion and spinal nerve injury [22, 23] . CCL2 enhances the excitability of dorsal root ganglion nociceptive neurons [24, 25] and potentiates Nmethyl-D-aspartate (NMDA)-induced currents in spinal neurons [23] , while a CCR2 antagonist suppresses the progressive enhancement of a nociceptive flexor reflex [26] , suggesting a role of CCL2-CCR2 signaling in spinal hyperexcitability and pain. Intradermal and spinal administration of CCL2 induce pain hypersensitivity [23, 27, 28] . In mice over-expressing CCL2
in astrocytes under the control of the glial fibrillary acidic protein (GFAP) promoter, the complete Freund's adjuvantinduced thermal hyperalgesia is significantly enhanced [29] .
On the other hand, neutralizing CCL2 or blocking CCR2
attenuates neuropathic pain behavior [17, 23, 26, 30] .
Despite increasing evidence on the role of immune cells and related chemicals in mechanisms of pain, few studies have addressed the potential role of chemokines in the descending facilitation of persistent pain [31] . The present study was undertaken to test the hypothesis that CCL2
signaling in the RVM is involved in descending pain facilitation. Our results suggest activation of the chemokine CCL2 signaling pathway in RVM modulatory circuitry after peripheral nerve injury. The release of CCL2 from neurons and the subsequent activation of its CCR2 receptor on microglia may represent a mechanism of neuron-glial interaction that is involved in the descending facilitation of neuropathic pain-like behavior in rats. Western blot) from Sigma-Aldrich; as well as mouse anti-GFAP (1:2 000 for immunohistochemistry), rabbit anti-IL-1β
Materials and methods

Drugs and antibodies
(1:500 for Western blot; 1:1 000 for immunohistochemistry) and mouse anti-NeuN (1:1 000 for immunohistochemistry)
from Millipore (Billerica, MA, USA).
Animals and nerve ligation procedure Male
Sprague-Dawley rats (Harlan, Indianapolis, IN, USA) were used in all experiments. All animal procedures were approved by the Institutional Animal Care and Use Committee of the University of Maryland, School of Dentistry.
The L5 spinal nerve ligation (L5-SNL) rat model was produced as described by Kim and Chung [32] . Briefly, the rats were anesthetized with sodium pentobarbital (50 mg/kg, i.p.). After shaving and sterilizing the skin with providoneiodine solution, a 1-1.5-cm midline skin incision was made and the left paraspinal muscles were separated from the spinous processes at the lumbosacral level. The L6
transverse process was carefully removed with a small rongeur to visually identify the L4-L5 spinal nerves. The L5 spinal nerve was isolated and tightly ligated with 6-0 silk. The muscle layers were sutured and the skin incision was closed. Post-surgical signs of infection or overt signs of discomfort were closely monitored. The animals were housed in cages in which the floor was covered with soft bedding materials to minimize discomfort due to contact with a cold, hard surface. Food and water were available ad libitum. Animals with hind-paw neuropathy groomed normally and displayed normal locomotor activity, but tended to guard the afflicted paw. The behavioral studies involved stimulation that produced only momentary pain and the rats could escape from these stimuli at any time.
Chronic cannula implantation and microinjec-
tion Cannulas for microinjection of drugs into the RVM were implanted 5-7 days prior to L5-SNL or pharmacological experiments. Animals were securely placed into a stereotaxic device (Kopf, Model 900) with the skull level between bregma and lambda. A guide cannula (26-gauge, C315G, Plastics One, Roanoke, VA, USA) was implanted using standard stereotaxic procedures (AP: 11.0; L: 0.0; D: 9.5 mm) [33] into the RVM under anesthesia with pentobarbital sodium (50 mg/kg i.p. [34] . Kiel, WI, USA) was used to deliver mechanical stimulation. The bending force of the filaments was in the range from 9 mg to 257 g. The testing method is described in detail elsewhere [35] . The testing filament was probed against the lateral edge of the hindpaw. The filaments were applied in an ascending series. A descending series of filaments was used when the rat responded to the starting filament. Each filament was tested 5 times at an interval of a few seconds. If paw withdrawal due to stimulation was observed, it was defined as a response to a filament. was set at 118 g for the non-injured paw for analysis since the responses were limited to a few high intensity fila-ments with large force intervals. A leftward shift of the S-R curve [36] , resulting in a reduction of EF 50 , occurred after L5-SNL. This shift suggested the presence of mechanical hyperalgesia and allodynia since there was an increase in response to suprathreshold stimuli and a decreased response threshold for nocifensive behavior.
Western blot Rats were anesthetized with isoflurane
(3%) and quickly decapitated. A block of brainstem from post-interaural line 1.3 mm to 2.5 mm was dissected and put immediately into dry ice. RVM tissues from the ventral half and middle portion of the rostral medulla [33] were and Cy3 after incubation with respective primary antibodies.
Control sections were processed with the same method except that the primary antisera were omitted or adsorbed by respective antigens.
Data analysis Data are presented as mean ± SEM.
Statistical comparisons were made by using ANOVA with
Fisher's PLSD test for post-hoc analysis. For Western blot analysis, the ECL-exposed films were digitized and densitometric quantification of immunoreactive bands was carried out using UN-SCAN-IT gel (version 4.3, Silk Scientific Inc., Orem, Utah, USA). The relative protein level was expressed as the ratio of a specific band to the β-actin control from the same membrane. The deduced ratio was further normalized to that of naive rats on the same membrane and illustrated as percentage of the naive control.
ANOVA and the unpaired 2-tailed t-test were used to determine significant differences. For the animals that were subject to repeated testing, ANOVA with repeated measures was used with time as a within-animal effect. P ≤0.05
was considered statistically significant.
Results
Spinal nerve injury upregulates CCL2/CCR2 expression in RVM
We first examined the levels of CCL2 expression in the RVM following L5-SNL injury. Compared to naive and sham-operated (not shown) rats, RVM sections exhibited increased CCL2 immunostaining after L5-SNL (Fig. 1A, B) . Western blot analysis confirmed that upregulation of CCL2 was significant at 1-21 days (P < 0.05, n = 3) and returned to the control level at 28 days after SNL (Fig. 1C) . Double immunofluorescence staining showed that CCL2 colocalized with the neuronal marker NeuN (Fig. 1D ), but not with the astroglial marker GFAP (Fig.   1E ) or microglial marker CD11b (Fig. 1F) in the RVM.
The upregulation of CCL2 was accompanied by an increased expression of its receptor CCR2 in the RVM ( Fig.   2A, B) . Western blot analysis showed that the intensity of the CCR2 immunoband was significantly increased during the 28-day observation period (P ≤0.05, P ≤0.01, n = 3), except at the 7-day time point (Fig. 2C) , which is likely an outlier. The CCR2 immunostaining in the RVM predominantly overlapped with CD11b (Fig. 2D) .
Besides, weak CCR2 staining was seen in some neurons as indicated by NeuN staining (Fig. 2E) . However, CCR2 immunoreactivity did not appear to be colocalized with GFAP (Fig. 2F ). (Fig. 3C ).
Antagonism of CCL2 in RVM attenuates
Administration of CCL2 into the RVM induces
pain hypersensitivity To mimic the nerve injury-induced effect on nociception, we next examined the effect of direct application of CCL2 into the RVM on nocifensive behavior in naive rats. Compared to vehicle, injection of CCL2
(0.03-3 pmol, n = 4) produced a dose-dependent reduction of PWL to noxious thermal stimuli (Fig. 4A ). In addition, pretreatment with RS-102895 (10 pmol, n = 4) reversed CCL2 (3 pmol)-induced thermal hyperalgesia (Fig. 4B) .
These results are consistent with a role for CCL2 in the descending facilitation of nociception and hyperalgesia. The CCL2 receptor CCR2 was mainly localized in microglia in the RVM (Fig. 3) . We then examined the effect of CCL2 on RVM microglia. CD11b immunostaining in the RVM clearly increased after administration of CCL2 compared to saline injection (Fig. 4C-G) , suggesting that CCL2 induced microglial reactivity.
The hyperalgesic effect of CCL2 in RVM is down-
stream to IL-1β signaling Studies indicate that the prototypic proinflammatory cytokine IL-1β is a strong inducer of CCL2 synthesis and release from neurons [19] . We next determined whether the IL-1β signaling pathway interacts with CCL2-CCR2 signaling in the RVM. Following L5-SNL, IL-1β was upregulated in the RVM (Fig. 5 ). An example of increased IL-1β immunostaining at 28 days after L5-SNL compared to naive rats is shown in Fig. 5B . Western blot analysis showed that the intensity of the IL-1β
immunoband was increased during the 28-day observation period (P ≤0.05, P ≤0.01, n = 3), except that the increase did not reach statistical significance at 7-day point (Fig.   5C ). Double immunofluorescence staining showed that IL-1β immunoreactivity was selectively localized in RVM reactive astrocytes, as indicated by overlap labeling of IL-1β with GFAP ( Fig. 5D ), but not with NeuN or CD11b (data not shown). The upregulation of astrocytic IL-1β in the RVM after L5-SNL is consistent with that following injury of the infraorbital nerve [6] .
Furthermore, injection of IL-1β (120 fmol) into the RVM induced a significant reduction of PWL to a noxious thermal stimulus, indicating behavioral hyperalgesia. Pretreatment with RS-102895 (10 pmol) 10 min prior to IL-1β injection blocked the IL-1β-induced reduction in PWL (Fig.   6A ). However, pretreatment with IL-1ra (3 pmol) did not prevent CCL2 (3 pmol)-induced thermal hyperalgesia, although there was a small reduction at 90 min (P <0.05) (Fig.   6B ). These results suggest that, in the RVM, the effect of CCL2 is downstream to IL-1β signaling. 
Discussion
Among inflammatory chemokines, the role of CCL2
in pain hypersensitivity has attracted considerable attention [12] . Here we showed that CCL2 in the RVM, a pivotal site in the brainstem pathway, was upregulated after spinal nerve injury. We further showed that L5 spinal nerve injury selectively upregulated neuronal CCL2 and its receptor CCR2, mainly associated with microglia, in the RVM.
Neutralizing CCL2 and microinjection of the CCR2 antagonist RS-102895 into the RVM significantly attenuated the SNL-induced behavioral hyperalgesia. Direct injection of CCL2 into the RVM induced dose-dependent hyperalgesia that was prevented by pretreatment with RS-102895. Interestingly, in rats receiving an L5 spinal nerve injury, IL-1β, an upstream inducer of neuronal CCL2, was selectively upregulated in RVM reactive astrocytes. Injection of IL-1β into the RVM induced behavioral hyperalgesia, which was 
Injury-induced CCL2 and CCR2 CCL2 normally
exists in immune and immune-related cells and functions to attract leukocytes, including monocytes and macrophages, to sites of injury [37, 38] . Although it was initially found that the constitutive expression of CCL2 appeared low in neural tissues by in situ hybridization [39] , further study showed clear neuronal expression of CCL2 in the rat brain [40] . In the present study, unilateral L5-SNL induced a selective increase in CCL2 expression in RVM neurons, as indicated by its colocalization with NeuN (a neuronal marker), but not with GFAP, a marker of astrocytes, or CD11b, a marker of microglia. Thus, our results suggest that neurons are at least the major, if not the exclusive, source of CCL2 in the RVM after injury. However, CCL2 may also be released from other sources in other regions. For example, SNL induces CCL2 in spinal astrocytes [23, 41] . Previous studies have found pain-related expression of CCL2 in the nervous system after injury [14, 23, 42] . Corresponding with the development of neuropathic pain behavior, CCL2 expression in dorsal root ganglion and spinal neurons is induced after chronic constriction or partial ligation injury of the sciatic nerve [14, 42] .
CCL2 is the main ligand for CCR2, the G proteincoupled chemokine receptor that also binds CCL7 (MCP-3), CCL8 (MCP-2) and CCL13 (MCP-4) [38] . We showed that CCR2 was also upregulated in the RVM after L5-SNL. A diverse distribution of CCR2 in neurons and nonneuronal cells has been shown in the nervous system [43] [44] [45] .
Similar to CCL2, CCR2 is inducible in the nervous system in addition to its constitutive expression in neurons and non-neuronal cells. Banisadr et al. [44] show that constitutive expression of CCR2 is only observed in neurons and astrocytes in adult rat brain, but is induced in microglia by lipopolysaccharide. CCR2 is induced in spinal microglia after partial sciatic nerve injury [20] . Consistently, our results showed that CCR-2 was selectively induced in microglia in the RVM by L5-SNL, suggesting that enhanced chemokine signaling also occurs in the supraspinal painmodulatory circuitry. However, using transgenic reporter mice with fluorescence-labeled CCL2 and CCR2 proteins,
Jung et al. [46] showed that CCL2-induced CCR2 receptor activation mainly occurs in the peripheral nervous system, including injured peripheral nerve and dorsal root ganglia, but not in the spinal parenchyma.
The upregulation of CCL2 in neurons and CCR2 in microglia in the RVM supports the concept of interactions between neurons and glia involving chemokine signaling.
CCL2-to-CCR2 signaling is critical for the migration of hematogenous macrophages and monocytes to the spinal cord after nerve injury [21] . Infiltrated macrophages and monocytes differentiate into microglia whose enhanced activity facilitates persistent pain. It is conceivable that CCL2 attracts microglia to migrate to synaptic sites and contribute to injury-induced synaptic plasticity [47] .
CCL2 signaling and descending pain facilitation
The contribution of neuron-glial interactions in the supraspinal pain-modulatory circuitry to persistent pain has only been recognized recently [48] . While persistent pain is facilitated by increased astroglial and microglial activity and upregulation of the prototypic inflammatory cytokines IL-1β and tumor necrosis factor-alpha (TNF-α) in the RVM after tissue and nerve injury [6, 48, 49] , the potential contribution of chemokines has not been studied. Our convergent results indicate that CCL2 signaling in the RVM promotes pain hypersensitivity. In agreement with the upregulation of CCL2 and CCR2, antagonism of CCL2-CCR2 attenuates and CCL2 agonist stimulation enhances nocifensive behavior.
The selective cellular localization of CCL2 and CCR2
observed in the present study suggests that neuronal activation after peripheral injury leads to secretion of the CCL2 chemokine that in turn acts on CCR2 receptors on microglia. CCL2 is released from primary afferent fibers into the spinal cord after sciatic nerve injury [17, 28] . CCR2
is expressed in microglia [50] . Partial sciatic nerve ligation leads to the appearance of CCR2-positive microglia in the spinal cord [20] and intraspinal injection of CCL2 activates microglia [28] . We showed that injection of CCL2 into the RVM also activated microglia, as indicated by increased CD11b immunoreactivity.
Studies suggest that IL-1β is capable of inducing CCL2 in the brain. A single systemic injection of IL-1β leads to increased CCL2 mRNA expression, mainly in vascular-associated structures, in the brain [39] . IL-1β significantly enhances CCL2 gene expression and its protein product in primary cortical neurons of mice [19] .
Our behavioral pharmacological data showed that IL-1β-induced hyperalgesia was blocked by a CCR2 antagonist but CCL2-induced hyperalgesia was not blocked by IL1ra. It is possible that the lack of an effect of IL-1ra on CCL2-induced hyperalgesia is due to an insufficient dose, although the same dose in the RVM has been shown to attenuate nerve injury-induced behavioral hyperalgesia in rats [6] . Thus, our results suggest that IL-1R activation in the RVM is upstream to CCL2 signaling.
IL-1β has been identified as a key component in neuron-
glial interactions in pain hypersensitivity [6, 51] . Peripheral activity [52] . These reciprocal interactions result in increased descending pain facilitation (Fig. 7) .
Alternative mechanisms for CCL2-induced pain facilitation should also be appreciated. CCL2 may act at a neuronal site that is upstream to its effect on microglia ( Fig.   7) . At the spinal level, CCL2-induced hyperalgesia depends upon NMDA receptor activation and IL-1ra partially blocks CCL2-induced hyperalgesia [53] . CCR2 expression in neurons [23, 45, 54] and enhancement of NMDA-induced current in spinal neurons by CCL2 [23] also support this possibility.
We also noted an increased immunoreactivity for CCR2 in RVM neurons after L5-SNL. Thus, CCR2 may also inter-act with NMDA receptors in neurons in pain pathways. All of these effects of CCL2 favor pain hypersensitivity.
In perspective, our results support the current view that glial cells interact with neurons in the development of pain hypersensitivity [7, 8, 10, 11, 13] . RVM glial hyperactivity and inflammatory cytokine/chemokine release affect or facilitate neuronal plasticity through interactions with neurons. Studies have shown that the receptors of inflammatory cytokines such as IL-1β and TNF-α colocalize with neuronal NMDA receptors [6, 51] . Signal coupling between cytokine and NMDA receptors may lead to increased descending output from pain modulatory neurons that facilitates spinal nociceptive transmission and intensifies perceived pain [52, 55] . 
